Germans Prioritize Modern Drug Access Over Stable Premiums, Survey Finds
Germans prioritize access to modern medicines over stable insurance premiums, a new Civey survey commissioned by Pharma Deutschland shows.
The Tech TL;DR:
- 52.1% of statutory insurance holders rank modern drug access above contribution stability; 40.5% prefer stable premiums.
- 90.4% consider it important that their insurance covers all modern drugs regardless of fund choice.
- 57.9% of never-switchers would change funds if theirs denied a physician-recommended modern drug.
The representative poll, reported first by Berliner Morgenpost, surveyed statutory health insurance members after the Bundestag passed the GKV-Finanzstabilisierungsgesetz. The law tightens mandatory discounts manufacturers must grant insurers and expands rebate contracts that can restrict prescribing choices.
“Dass die Krankenkassen und die Politik mit dem GKV-Spargesetz sehenden Auges den strategisch so wichtigen Pharmastandort Deutschland schwächen, ist das eine,” Pharma Deutschland Chief Executive Dorothee Brakmann told Berliner Morgenpost.
“Die Umfrage zeigt aber, dass der zu erwartende Schaden weit darüber hinausgeht. Nicht nur das Vertrauen der Unternehmen wird durch die gegenwärtigen harten Einschnitte auf eine ernste Probe gestellt. Auch die Versicherten merken, dass sie das Spargesetz mit Einschränkungen in der Versorgung bei schwerwiegenden Erkrankungen werden bezahlen müssen.”
AbbVie Germany Managing Director Thibault Massart echoed the concern. “Welche modernen Medikamente ein Mensch bekommt, sollte nicht davon abhängen, bei welcher gesetzlichen Krankenkasse er versichert ist,” Massart told Berliner Morgenpost. “Moderne Medikamente gegen dieselbe Erkrankung könnten unterschiedliche Wirkstoffe haben und sich in Wirkung und Nebenwirkungen unterscheiden. Deshalb sollte die Entscheidung beim Arzt oder der Ärztin liegen und nicht bei Rabattverträgen der Krankenkassen.”
71.1% of respondents expect the current health reform to worsen their personal medical care. Only 6.9% consider unrestricted access to modern drugs across all funds unimportant.
When cost-cutting measures limit the selection of modern medicines, 69.7% rate the impact as very negative and another 15.2% as rather negative.
Among members who have never changed insurers, 57.9% say they would definitely or probably switch if their fund refused to cover a doctor-recommended modern drug that another fund covers. 26.4% would stay; 15.7% are undecided.
Statutory health insurance in Germany operates under mandatory membership with standardized core benefits, but funds differentiate through supplementary statutes and rebate-driven formularies. The GKV-Finanzstabilisierungsgesetz, enacted late 2022 and amended through 2023, increased the mandatory manufacturer discount from 7% to 12% for patented medicines and expanded the scope of discount contracts insurers can sign.
Rebate contracts (Rabattverträge) bind insurers to specific products in exchange for price concessions. Physicians must prescribe the contracted product unless they document medical reasons for deviation.
Pharma Deutschland represents research-based pharmaceutical companies in Germany.
“Ein Gesetz, das die Versicherten verunsichere und dem Pharmastandort schade, sei kein zukunftsfähiges Konzept,” Brakmann said.
- Urinary Protein Profiles May Help Subtype and Detect Early-Stage Feline Chronic Kidney Disease
- The 2026 El Niño has reached unprecedented intensity
- Median Net Worth Peaks at 75+ in the Fed's Survey, but the Lead Is Thin (daybreakwire.com)
- Colorectal Cancer Rates Rise After 20-Year Decline, Study Finds (time.news)